Akesobio readies Hong Kong listing
Chinese biopharmaceutical firm Akesobio has got the greenlight from the Hong Kong Stock Exchange for its IPO, which is expected to raise $200m to $300m, according to a source familiar with the matter.
After winning listing approval, the issuer submitted its post-hearing prospectus to the bourse on Monday. JP Morgan and Morgan Stanley are running the show as the sponsors, and are in talks with investors for the transaction.Akesobio initially filed an IPO application on December 3, 2019, but ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org